CCDC17 Inhibitors
CCDC17 Inhibitors comprise a spectrum of chemical entities that suppress the functional activity of CCDC17 by interfacing with various cellular pathways. LY 294002 and Wortmannin, both phosphatidylinositol 3-kinase (PI3K) inhibitors, are anticipated to diminish CCDC17 activity by impeding the PI3K/Akt signaling pathway, which is integral to cell growth and survival, processes where CCDC17 may play a role. Similarly, PD 98059 and U0126 are selective inhibitors of the MAPK/ERK pathway, which, if associated with CCDC17 function, would result in reduced activity due to the blockade of this proliferative and differentiative signaling. SB 203580 and SP600125 target p38 MAPK and JNK pathways, respectively, both involved in inflammatory and stress responses, and their inhibition could lead to suppressed CCDC17 activity if it is contingent on these pathways.
The second set of inhibitors, including Rapamycin, Y-27632, and Gö 6983, act upon mTOR, ROCK, and PKC, respectively. Rapamycin's inhibition of mTOR signaling could indirectly reduce CCDC17 activity if it is part of the cellular growth or metabolism circuits regulated by mTOR. Y-27632's effect on ROCK potentially impacts CCDC17 activity by altering cytoskeleton organization and cell motility, while Go6983's inhibition of PKC may affect CCDC17 if it is involved in PKC-mediated signaling processes. BAPTA/AM, a calcium chelator, and Thapsigargin, a SERCA pump inhibitor, both influence calcium signaling where BAPTA-AM's chelation of intracellular calcium could lead to decreased CCDC17 activity if it is calcium-dependent, and Thapsigargin's dysregulation of calcium homeostasis could indirectly diminish CCDC17 function if it is negatively regulated by calcium. Lastly, Dorsomorphin, an AMPK inhibitor, could reduce CCDC17 activity by affecting cellular energy homeostasis mechanisms that CCDC17 might be involved in. Collectively, these inhibitors represent a strategic approach to diminish CCDC17 activity by targeting specific pathways that are critical to its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Phosphatidylinositol 3-kinase (PI3K) inhibitor that blocks PI3K/Akt signaling pathway. Since the PI3K/Akt pathway is involved in numerous cellular processes including cell growth and survival, inhibition by LY 294002 could lead to decreased stability or interaction of CCDC17 with other cellular components, potentially reducing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A steroidal metabolite that acts as a potent PI3K inhibitor. Similar to LY294002, by inhibiting the PI3K/Akt pathway, Wortmannin could indirectly lead to a reduction in CCDC17 activity due to alterations in cellular survival and growth mechanisms where CCDC17 might play a part. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that blocks the MAPK/ERK pathway. If CCDC17 activity is linked to the MAPK/ERK pathway, which is involved in cell proliferation and differentiation, PD 98059 could decrease CCDC17 activity by preventing pathway signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, U0126 would inhibit the MAPK/ERK signaling pathway. By disrupting this pathway, U0126 could diminish the activity of CCDC17 if it is related to or dependent on the downstream effects of MAPK/ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can lead to reduced inflammatory responses and cellular stress signaling, potentially diminishing CCDC17 activity if it is linked to these cellular responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK). The JNK pathway is involved in stress responses and apoptosis. Inhibition with SP600125 could lead to decreased CCDC17 activity by altering the stress response pathways that CCDC17 may be involved with. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that impacts cell growth and metabolism. By inhibiting mTOR, Rapamycin could indirectly decrease CCDC17 activity if CCDC17 has a functional role related to cell growth or metabolism regulated by mTOR signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor impacting cytoskeleton organization and cell motility. If CCDC17 is involved in cellular structure or movement, inhibition of ROCK by Y-27632 could result in decreased CCDC17 activity as it might affect the cellular architecture. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Protein kinase C (PKC) inhibitor that may alter a variety of cellular functions. If CCDC17 activity is associated with PKC-related signaling, Gö 6983 could diminish its activity by inhibiting PKC-dependent processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Intracellular calcium chelator that can disrupt calcium signaling. If CCDC17 is involved in calcium-dependent processes, BAPTA/AM could diminish its activity by altering intracellular calcium levels. | ||||||